Caner Saygin, MD
@CanerSaygin
Leukemologist @UChicago | Alumni of @UCHemOncFellows, @OhioStateIMRes, @CCLRI | #Leukemia, #MDS, #CHIP physician-scientist. Tweets=own opinions.
new work in @BloodJournal featuring @CanerSaygin as co-author looking at type 2 CALR mutations and BCL-xL in MPNs! pubmed.ncbi.nlm.nih.gov/40403318/
Congratulations @nsarellano9 and @TheElfLab! Beautiful story, very well done!
Out at last in @BloodJournal!! doi.org/10.1182/blood.… So very proud of @nsarellano9 and team! Nicole conceived of this project as a 19 year old undergrad in my brand new lab, and 6 years of (literal) blood, sweat and tears later, here she is in all her glory!
We need to simplify ALL classification in adults. Several of these fusions are either not present or not clinically-tested due to lack of therapeutic/prognostic relevance. Both WHO and ICC schemes are distracting clinicians and preventing them from focusing on what’s relevant.
Genetic subtypes of B-cell acute lymphoblastic leukemia in adults ashpublications.org/blood/article-… #leusm
check out this new paper featuring @CanerSaygin as co-author which looks at the impact of TP53 mutations and TET2 deficiency on leukemogenesis! pubmed.ncbi.nlm.nih.gov/40111422/
Submit an abstract by December 30 for the AACR Special Conference on Acute Lymphoblastic Leukemia (March 7-9, San Diego), organized in association with the AACR Hematologic Malignancies Working Group. Learn more: aacr.org/meeting/aacr-s… #aacrALL25
🩸 @UChicagoMed faculty and trainees presented ground breaking research and advancements in blood cancers at a recent #ASH Annual Meeting. 🧬📰 @UChicagoHemOnc @UChicagoLeuk Check out the full list of presentations here 👉 ow.ly/TRFW50Uv9lt
#ASHKudos to Kathryn Shimamoto on receiving abstract achievement award for her wonderful work👏👏👏 #ASH24 @Kateshimamoto @CanerSaygin @UChicagoHemOnc @UChicagoLeuk
So proud of these amazing mentees presenting their exciting leukemia research at #ASH24 @HabibElKhoury @Kateshimamoto @EPostich @DArdaKaraoglu @MedChiefs @UCCancerCenter @UChicagoLeuk
Jennifer Cooperrider, MD presented incredible data today at #ASH showing TP53 clone stability after discontinuation of treatment in multiple myeloma pts. @bdermanmd @CanerSaygin @UChicagoHemOnc @UChicagoLeuk
Jen Cooperrider presenting cool data on how TP53-mutant CH progresses during myeloma therapy. So proud of our team! @DArdaKaraoglu #ASH24 @UCCancerCenter
If you are interested in hearing about how lenalidomide maintenance and discontinuation effect TP53-mutant clonal hematopoiesis, come and see our data at Marriott Pacific Ballroom at 2 pm. #ASH24 @UChicagoHemOnc
Join Jennifer Cooperrider, MD as she discusses the data on the status of clonal hematopoiesis after discontinuation of treatment in multiple myeloma patients from MRD2STOP trial. #mmsm #myeloma #TP53 @UChicagoHemOnc @UChicagoLeuk ow.ly/Ee5050UmZzu
And Saygin lab meets the famous Red! @DArdaKaraoglu @EPostich #ASH24
Spotted some of the trainees from @UCCancerCenter leukemia team having good time at #ASH24 ash-a-palooza with the white! @EPostich @Kateshimamoto @DArdaKaraoglu @UChicagoHemOnc